21 results about "N gonorrhoeae" patented technology

Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and / or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.

This invention provides bfrA Single gene knockout or bfrA Genes and bfrB Double gene knockout of Neisseria gonorrhoeae and its applications involve the field of biotechnology. Research has found that... bfrA Single gene knockout and bfrA and bfrB Double gene knockout of Neisseria gonorrhoeae resulted in increased formation of vesicles on the outer membrane, disruption of the cell wall and cell membrane, reduced adhesion and invasion abilities, decreased bacterial activity, decreased ATP levels, and weakened ability to infect mice. Therefore, knocking out Neisseria gonorrhoeae... bfrA Gene or bfrA and bfrB The dual-gene assay can be used to prepare products for the production of gonococcal outer membrane vesicles and to construct low-pathogenic gonococcal models.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria spp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria spp and sensitizing Neisseria spp to antibiotic treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to a neisseria gonorrhoeae chromogenic culture medium. According to the chromogenic culture medium, a supplement and a composite bacteriostatic agent are additionally added into a gonococcus culture medium, and the supplement is prepared from 50-200 ml / L of horse serum, 1-20 mg / L of hemin chloride, 25-250 mg / L of L-proline beta-naphthylamide hydrochloride, 500-5000 mg / L of 1, 3, 4-trimethyl-1, 3-pentanediol monoisobutyrate, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride and 10-20 mg / L of sodium chloride. The invention relates to a neisseria gonorrhoeae culture medium, which is characterized in that neisseria gonorrhoeae in a sample can be directly separated and identified by adopting the culture medium, and a separated bacterial colony can be directly used for a drug sensitive test. The neisseria gonorrhoeae can be directly separated and identified by adopting the neisseria gonorrhoeae culture medium for the drug sensitive test of neisseria gonorrhoeae in the sample.

Described herein are vaccine compositions and methods of selecting an antigen or fragment thereof for the preparation of a vaccine composition. The methods and vaccine compositions described herein are based, in part, on the discovery that certain polypeptides not previously identified or considered for potential use as antigens from pathogenic microorganisms (e.g., N. gonorrhoeae) can provoke an immune response in a subject. The methods of identifying and selecting the antigens described herein rely, in part, on approaches that identify polypeptides (e.g., hypothetical proteins) predicted to be immunogenic.

The invention relates to a method for detecting the presence of at least two pathogens in a sample, wherein additionally subtypes and / or variant-derived properties such as treatment susceptibility are determined. The method may be a polymerase chain reaction and may be facilitated by a cartridge and dried reagents. The pathogens may be bacterial pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae. The invention further relates to a cartridge and / or a cartridge reader for performing the method of the invention.

The invention provides application of tripterine or a derivative thereof in preparation of a product for inhibiting neisseria gonorrhoeae, and relates to the technical field of biology and bacteriostasis. The invention particularly relates to application of tripterine or a derivative thereof in preparation of a neisseria gonorrhoeae inhibitor; or (II) application in preparation of a medicine for preventing, relieving and / or treating neisseria gonorrhoeae infection; the invention relates to a medicine for treating or preventing infection and / or complications caused by neisseria gonorrhoeae and a method for inhibiting or preventing growth of neisseria gonorrhoeae.

The invention belongs to the technical field of biology, and provides a chlamydia trachomatis and gonococci double-target immunochromatography detection method which comprises the following steps: introducing a dibenzocyclooctyne group to the tail end of lipopolysaccharide of the chlamydia trachomatis, introducing a trans-cyclooctene group into outer membrane protein of gonococci, and detecting the chlamydia trachomatis and gonococci double-target immunochromatography. In the chromatographic detection process, the antibody can form two non-interfering detection channels with an anti-lipopolysaccharide antibody containing an azide group and an anti-outer membrane protein antibody containing a tetrazine group. Through the improvement, the problem that a high-concentration antigen occupies a binding site or interferes with a chromatography process due to nonspecificity can be avoided, and high specificity and high sensitivity of detection are ensured.

This invention relates to the field of biomedical detection technology, specifically to plasma circulating microbial biomarkers for early screening of gastric cancer and their applications. The plasma circulating microbial biomarkers include: *Ralstonia solanacearum*, *Staphylococcus aureus*, *Alternaria metachromatica*, *Porphyromonas gingivalis*, *Lactobacillus reuteri*, *Rhodococcus erythropolis*, *Akkermansia muciniphila*, *Lactobacillus gasseri*, *Bifidobacterium bifidum*, and *Neisseria gonorrhoeae*. This invention screens and, for the first time, combines 10 specific microbial biomarkers with Low Pass technology. WGS technology can achieve detection results at low depths, significantly reducing screening costs while ensuring detection sensitivity, and providing a brand-new solution for early gastric cancer screening.

Immunogenic and vaccine compositions containing a Neisseria gonorrhoeae lipooligosaccharide (LOS), or a fragment thereof, are provided. The LOS may be conjugated to a carrier such as a carrier protein, virus-like particle (VLP), liposome, inorganic gold particle, dendrimer, outer membrane vesicle (OMV), generalized modules for membrane antigens (GMMA), and protein nanocages. Methods of protecting or treating a subject from Neisseria gonorrhoeae infection and methods of manufacturing the compositions are also provided.

Isolated antigen binding polypeptides having a heavy chain variable region and / or light chain variable region that specifically binds to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae as well as antibodies and antigen binding antibody fragments containing the heavy chain variable region and / or the light chain variable region that bind to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae are provided. Pharmaceutical compositions and kits comprising the isolated antigen binding polypeptide and antibodies or antigen binding antibody fragments thereof comprising the antigen binding polypeptide are also provided, along with methods of treating an infection caused by Neisseria gonorrhoeae and methods of making the polypeptides, antibodies and antigen-binding antibody fragments.

In some aspects, the disclosure relates to compositions of peptide mimics useful in the treatment of Neisseria gonorrhoeae (N. gonorrhoeae). In some embodiments, the peptide mimics are multi-antigenic molecules of a conserved gonococcal lipo-oligosaccharaide (LOS) epitope. In some aspects, the disclosure relates to methods of making peptide mimics for the treatment of N. gonorrhoeae. In some aspects, the disclosure relates to methods of using peptide mimics for the treatment of N. gonorrhoeae.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria sp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria sp.

The invention relates to a composition comprising OMVs obtained from a modified Neisseria gonorrhoeae strain expressing a PorB variant, methods for preparing said composition, and its uses including vaccines.

The invention relates to an essential oil composition extracted from Chinese herbal medicines, which has a killing effect on neisseria gonorrhoeae and is suitable for treating urogenital system infection and pharyngolaryngitis. The liquid medicine is prepared from the following Chinese herbal medicine essential oil in parts by weight: 6-40 parts of peppermint essential oil, 12-31 parts of oregano essential oil, 14-80 parts of eucalyptus oil, 10-65 parts of chamomile essential oil, 15-75 parts of tea tree essential oil, 17-80 parts of balm essential oil and 9-27 parts of thyme essential oil. The invention relates to a Chinese herbal medicine powerful bactericidal composition with fragrant smell, and the bactericidal rate gt of neisseria gonorrhoeae; the yield is 99.97%. The traditional Chinese medicine composition is safe to use, has no irritation to skin mucous membrane tissues, also has a lubricating effect, and creates another new chapter in China and even in the world in the technical field of medicines for treating infectious diseases by utilizing the safe and powerful bactericidal and antibacterial characteristics of Chinese herbal medicines. The method can be widely applied to the fields of medicines, health care products, antibacterial and bacteriostatic hygienic products and the like.

The application provides application of sorafenib in preparation of a product for inhibiting Neisseria gonorrhoeae, and relates to the technical field of biology and bacteriostasis. The application comprises application of sorafenib or a derivative thereof in (I) preparation of a Neisseria gonorrhoeae inhibitor; or (II) preparation of a medicine for preventing, relieving and / or treating Neisseria gonorrhoeae; a medicine for treating or preventing infection and / or complications caused by Neisseria gonorrhoeae; a method for inhibiting or preventing growth of Neisseria gonorrhoeae; and the application provides a new potential medicine selection for treating drug-resistant gonorrhea, and has important clinical application value.

The present application generally relates to compounds which are inhibitors of Neisseria gonorrhoeae. Compounds, pharmaceutical compositions and use thereof are within the scope of this disclosure.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including one or more recombinant nucleic acid sequence that encodes a synthetic antibody or synthetic multivalent antibody to the subject. The disclosure also provides a compositions and methods of preventing and / or treating a Neisseria gonorrhoeae infection in a subject using said synthetic antibody or synthetic multivalent antibody.

The invention discloses a therapeutic chimeric monoclonal antibody and application thereof. The monoclonal antibody M01 is obtained from a mouse of an immune polypeptide vaccine MAP-Loop2, and the MAP-Loop2 polypeptide vaccine is a polypeptide fragment designed on the basis of a neisseria gonorrhoeae MtrE protein Loop2 structure. All sequences of immunized mouse B cells BCR are obtained through single cell sequencing, and a variable region sequence with the highest occurrence frequency is screened and cloned to a human IgG1 antibody constant region for expression and purification and is named as M01. Researches prove that the M01 has preventive and therapeutic effects on neisseria gonorrhoeae infection in a mouse vaginal infection model. According to the invention, the chimeric antibody with the Loop2 structure and exposed on the surface of the neisseria gonorrhoeae MtrE protein is prepared, so that a complement-dependent antibody sterilization reaction is effectively initiated; neisseria gonorrhoeae infection is effectively treated, the problem of drug resistance enhancement caused by antibiotic treatment is avoided, and a new treatment means is provided for gonorrhoeae prevention and control.

The invention pertains to a genetically modified Neisseria bacterium comprising a lipopolysaccharide (LPS) having a lipid A moiety and a modified oligosaccharide core, wherein the modified oligosaccharide core comprises a first oligosaccharide chain coupled to heptose 1 and a second oligosaccharide chain coupled to heptose 2, wherein the first and second oligosaccharide chain comprise a lactose directly coupled to respectively heptose 1 and 2, thereby forming a Neisseria gonorrhoeae 2C7 epitope. The modified bacterium may express a further non-native N. gonorrhoeae antigen, such as MetQ, AniA or NspA. The modified Neisseria bacterium is not Neisseria gonorrhoeae. The bacterium is preferably Neisseria meningitidis, Neisseria lactamica or Neisseria cinerea. The invention further pertains to LPS and OMVs obtained from the genetically modified bacterium, as well as methods for producing said modified bacterium.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.